Published in Cancer Weekly, September 4th, 2007
"Twelve patients received ATRA-IV at three dose levels (60, 75, and 90...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.